TLR4 antagonist ameliorates combined allergic rhinitis and asthma syndrome (CARAS) by reducing inflammatory monocytes infiltration in mice model.
Sign Up to like & getrecommendations! Published in 2019 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2019.05.021
Abstract: The present study aims to investigate the effects of toll-like receptor 4 (TLR4) antagonist in an ovalbumin (OVA)-induced mouse model of combined allergic rhinitis and asthma syndrome (CARAS). An OVA-induced mouse model of CARAS was… read more here.
Keywords: allergic rhinitis; tak 242; combined allergic; infiltration ... See more keywords